Success Metrics

Clinical Success Rate

93.2%

Based on 41 completed trials

Completion Rate

93%(41/44)

Active Trials

6(10%)

Results Posted

34%(14 trials)

Terminated

3(5%)

Phase Distribution

Ph early_phase_1

12%

Ph phase_4

10%

Ph not_applicable

24%

Ph phase_3

Ph phase_1

24%

Ph phase_2

24%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution57 total trials

Early Phase 1First-in-human

7(12.3%)

Phase 1Safety & dosage

14(24.6%)

Phase 2Efficacy & side effects

14(24.6%)

Phase 3Large-scale testing

2(3.5%)

Phase 4Post-market surveillance

6(10.5%)

N/ANon-phased studies

14(24.6%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

89.1%

41 of 46 finished

Non-Completion Rate

10.9%

5 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(6)

Completed(41)

Terminated(5)

Other(6)

Detailed Status

Completed41

unknown5

Active, not recruiting4

Terminated3

Recruiting2

Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

93.2%

Most Advanced

Phase 4

Trials by Phase

Early Phase 17 (12.3%)

Phase 114 (24.6%)

Phase 214 (24.6%)

Phase 32 (3.5%)

Phase 46 (10.5%)

N/A14 (24.6%)

Trials by Status

recruiting23%

suspended12%

unknown59%

withdrawn23%

terminated35%

completed4171%

active_not_recruiting47%

Recent Activity

6 active trials

Showing 5 of 58

completedphase_1

Opioid Antagonism in Individuals Ascertained Through the Partners HealthCare Biobank

NCT04975347

View all 58 trials

Clinical Trials (58)

Showing 20 of 58 trialsScroll for more

NCT04975334Phase 1

Opioid Antagonism in Hypogonadotropic Hypogonadism

Completed

NCT03897998Phase 2

Neural Correlates of Hypoalgesia Driven by Observation

Completed

NCT05528848Phase 1

Multi-System Analysis of Opioid Receptor Binding

Active Not Recruiting

NCT04851301Phase 1

Neural Mechanisms of Immersive Virtual Reality in Chronic Pain

Active Not Recruiting

NCT04975347Phase 1

Opioid Antagonism in Individuals Ascertained Through the Partners HealthCare Biobank

Completed

NCT05490134Early Phase 1

RM1 Project 1 - tAN Naloxone

Recruiting

NCT05142267Not Applicable

Stress and Opioid Misuse Risk: The Role of Endogenous Opioid and Endocannabinoid Mechanisms

Recruiting

NCT02332447Phase 3

Efficacy of Naloxone in Reducing Postictal Central Respiratory Dysfunction in Patients With Epilepsy

Completed

NCT03608163Phase 4

Novel Approach for the Prevention of Hypoglycemia Associated Autonomic Failure (HAAF)

Terminated

NCT04744883Early Phase 1

Efficacy of Spinal Manipulation Therapy or Mindfulness-based Reduction Therapy on Patients With Chronic Low Back Pain

Active Not Recruiting

NCT05886712Not Applicable

Improving Access to Naloxone to Prevent Opioid Overdose Deaths (SAIA-Naloxone)

Active Not Recruiting

NCT03751111Phase 1

Treatment of Chronic Itch in Patients Under Arsenic Exposure With Naloxone

Completed

NCT05114460Phase 2

Vaped Marijuana to Attenuate Naloxone-Precipitated Withdrawal

Terminated

NCT03743805Early Phase 1

Rapid Reversal of CNS-Depressant Drug Effect Prior to Brain Death Determination

Withdrawn

NCT01952782Phase 1

Neuropeptides in Human Reproduction

Completed

NCT03176316Phase 4

The Use of Oral Naloxone to Prevent Post Spinal Fusion Ileus

Terminated

NCT02684669Phase 2

Effect of High-dose Target-controlled Naloxone Infusion on Pain and Hyperalgesia During a Burn Injury

Completed

NCT02976337Phase 2

Effect of High-dose Naloxone Following Third Molar Extraction

Completed

NCT04034004Early Phase 1

Chronic Low Back Pain and Meditation

Completed

NCT01367561Phase 1

Naloxone and Intravenous Methylnaltrexone Effects on Bladder Function

Completed

Drug Details

Intervention Type: DRUG
Total Trials: 58